The synergy of Notch inhibition and ADT has been demonstrated in ERG-driven prostate cancer in combination with both AR antagonists such as enzalutamide and inhibitors of androgen synthesis such as abiraterone [149]. The gene discussed is AR; the disease is prostate cancer.